Moleculin Biotech Publishes Peer-Reviewed Cardiac Safety Analysis of Annamycin

Moleculin Biotech, Inc. (MBRX) announced on September 28, 2026, that a peer-reviewed analysis of the cardiac safety of Annamycin (L-Annamycin or naxtarubicin) was published in Frontiers in Cardiovascular Medicine. The publication evaluates the drug candidate's cardiac profile, a key differentiator for anthracycline-based therapies. Annamycin is being developed as a next-generation anthracycline designed to avoid the cardiotoxicity associated with conventional treatments. The peer-reviewed analysis supports the company's positioning of the compound as a potentially safer alternative in its class. Moleculin did not disclose additional financial terms or trial timelines in the announcement. The publication provides third-party validation of the drug's cardiac safety data as the company advances its development programs.